Cannabichromene (CBC) is a minor cannabinoid within the array of over 120 cannabinoids identified in the Cannabis sativa plant. While CBC does not comprise a significant portion of whole plant material, it is available to the public in a purified and highly concentrated form. As minor cannabinoids become more popular due to their potential therapeutic properties, it becomes crucial to elucidate their metabolism in humans. Therefore, the goal of this was study to identify the major CBC phase I-oxidized metabolite generated in vitro following incubation with human liver microsomes. The novel metabolite structure was identified as 2′-hydroxycannabicitran using gas chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. Following the identification, in silico molecular modeling experiments were conducted and predicted 2′-hydroxycannabicitran to fit in the orthosteric site of both the CB1 and CB2 receptors. When tested in vitro utilizing a competitive binding assay, the metabolite did not show significant binding to either the CB1 or CB2 receptors. Further work necessitates the determination of potential activity of CBC and the here-identified phase I metabolite in other non-cannabinoid receptors.
8 August 2024 in Clinical and Translational Science
The OPRM1 gene codes for the mu opioid receptor (MOR) and polymorphisms are associated with complex patient clinical responses. The most studied single nucleotide polymorphism (SNP) in OPRM1 is adenine (A) substituted by guanine (G) at position 118 (118A>G, rs1799971) leading to a substitution of asparagine (Asn) for aspartic acid (Asp) at position 40 in the N terminus of the resulting protein. To date, no structural explanation for the associated clinical responses resulting from the 118A>G polymorphism has been proposed. We utilized computational modeling paired with functional cellular assays to predict unstructured N‐ and C‐terminal regions of MOR‐1. Using molecular docking and post‐docking energy minimizations with morphine, we show that the extracellular substitution of Asn at position 40 alters the cytoplasmic C‐terminal conformation, while leaving the G‐protein binding interface unaffected. A real‐time BRET assay measuring G‐protein and β‐arrestin association with MOR r generated data that tested this prediction. Consistent with this in silico prediction, we show changes in morphine‐mediated β‐arrestin association with receptor variants with little change in morphine‐mediated G‐protein association comparing MOR‐1 wild type (WT) to MOR‐1118A>G. We tested the system with different opioid agonists, the OPRM1 118A>G SNP, and different MOR splice variants (MOR‐1 and MOR‐1O). These results are consistent with the observation that patients with the 118A>G OPRM1 allele respond more readily to fentanyl than to morphine. In conclusion, the 118A>G substitution alters receptor responses to opioids through variable C‐terminal domain movements that are agonist and splice variant dependent.
12 August 2025 in Journal of Chemical Information and Modeling
Recent developments around inhibitors of the 90 kDa ribosomal S6 serine/threonine kinases (RSK1–4) have been focused on the optimization of known pan-RSK inhibitors such as SL0101 and BI-D1870. The RSKs are an intriguing target for cancer therapy due to their role as downstream effectors in the MAPK pathway. Herein, we focus on the utilization of computational modeling in inhibitor screening and development for RSK, and we examine computational artifacts in molecular modeling, quantum mechanical calculations, molecular dynamics, and high throughput screening. Variation between RSK structural models is also evident, given the available crystal structures, and liberties in homology modeling and dynamic conformations may capture new targeting approaches for these proteins. Furthermore, pan-kinase inhibitors are often used to target RSK since the four different RSK isoforms share a high degree of homology; however, they have distinct biological actions in cancer. A majority of RSK modeling generalizes the conclusions from one isoform onto the others; therefore, forming accurate isoform specific models containing their subtle differences will be key to the development of isoform-selective inhibitors. This review consolidates existing RSK models and the isoform specific structural differences that have and have not been considered, evaluates inhibition studies that have started to build upon RSK selectivity, including for its isoforms, and assesses other inhibitory binding sites to offer potential pathways forward. The leveraging of these differences through computational methods aims to guide next-generation isoform-selective RSK inhibitors.
The fundamental chemistries and electronic structures of platinum catalysts over nitrogen-doped carbon supports were examined to determine the subtle yet important roles graphitic defect-based and pyridinic defect-based nitrogen defects have in stabilizing platinum. These roles address and extend previously gathered incomplete knowledge of how combinations of graphitic defect and pyridinic defect affect the local electronic structure, leading to a greater unified understanding of platinum stability. A theoretical study was designed where different atomically sized platinum clusters were investigated over seven different nitrogen defect combinations on graphene carbon support. Differently sized platinum clusters offered parametric insights into the differences in metal–support interactions.